[{"id":"78368562-545f-4c40-b6de-f2d2cbfd2a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT07183865","created_at":"2025-09-27T08:40:54.392Z","updated_at":"2025-09-27T08:40:54.392Z","phase":"Phase 2","brief_title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","source_id_and_acronym":"NCT07183865","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/09/2025","start_date":" 03/09/2025","primary_txt":" Primary completion: 03/09/2030","primary_completion_date":" 03/09/2030","study_txt":" Completion: 03/09/2030","study_completion_date":" 03/09/2030","last_update_posted":"2025-09-19"},{"id":"710fbbdc-56f1-402d-9817-416d903d4d64","acronym":"SUPβORT","url":"https://clinicaltrials.gov/study/NCT07000305","created_at":"2025-06-07T14:45:31.114Z","updated_at":"2025-06-07T14:45:31.114Z","phase":"Phase 2","brief_title":"A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","source_id_and_acronym":"NCT07000305 - SUPβORT","lead_sponsor":"Tao Zhang","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/20/2025","start_date":" 05/20/2025","primary_txt":" Primary completion: 05/20/2027","primary_completion_date":" 05/20/2027","study_txt":" Completion: 05/20/2028","study_completion_date":" 05/20/2028","last_update_posted":"2025-06-02"},{"id":"8db1acf5-a900-4cd5-833c-3f33dc56134c","acronym":"IRIMAD","url":"https://clinicaltrials.gov/study/NCT06501482","created_at":"2025-02-26T14:30:19.761Z","updated_at":"2025-02-26T14:30:19.761Z","phase":"Phase 3","brief_title":"Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI","source_id_and_acronym":"NCT06501482 - IRIMAD","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2024-07-15"},{"id":"8fc59072-be3e-4c35-92de-8a0598e1cf53","acronym":"","url":"https://clinicaltrials.gov/study/NCT00082706","created_at":"2021-01-18T00:13:59.383Z","updated_at":"2024-07-02T16:35:02.799Z","phase":"Phase 2","brief_title":"Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant","source_id_and_acronym":"NCT00082706","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • 5-fluorouracil • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/23/2003","start_date":" 04/23/2003","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"1b5c72eb-5c58-41c6-a2fd-22f00febc998","acronym":"","url":"https://clinicaltrials.gov/study/NCT06002789","created_at":"2023-08-21T14:09:01.504Z","updated_at":"2024-07-02T16:35:20.355Z","phase":"Phase 2","brief_title":"Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC","source_id_and_acronym":"NCT06002789","lead_sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","biomarkers":" MSI • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-02-07"},{"id":"9b4eb02e-6a45-4510-a1dc-5481f38f9348","acronym":"","url":"https://clinicaltrials.gov/study/NCT02037048","created_at":"2024-01-08T18:17:04.164Z","updated_at":"2024-07-02T16:35:24.221Z","phase":"Phase 2","brief_title":"FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma","source_id_and_acronym":"NCT02037048","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 02/10/2014","start_date":" 02/10/2014","primary_txt":" Primary completion: 03/18/2022","primary_completion_date":" 03/18/2022","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-01-08"},{"id":"5d026fe8-d742-497c-a382-293da41307d7","acronym":"GASTFOX","url":"https://clinicaltrials.gov/study/NCT03006432","created_at":"2021-01-18T14:47:16.487Z","updated_at":"2024-07-02T16:35:43.295Z","phase":"Phase 3","brief_title":"PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA","source_id_and_acronym":"NCT03006432 - GASTFOX","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 507","initiation":"Initiation: 12/19/2016","start_date":" 12/19/2016","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-07-12"},{"id":"18969080-8eb0-4d96-a700-a81dd448f550","acronym":"SINTART2","url":"https://clinicaltrials.gov/study/NCT02099188","created_at":"2021-07-13T21:53:06.604Z","updated_at":"2024-07-02T16:35:53.438Z","phase":"Phase 2","brief_title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","source_id_and_acronym":"NCT02099188 - SINTART2","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • ifosfamide • etoposide IV • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-03-13"},{"id":"c76b2924-526d-4c0c-91ca-abc674c755d0","acronym":"SINTART 1","url":"https://clinicaltrials.gov/study/NCT02099175","created_at":"2021-07-13T21:53:06.298Z","updated_at":"2024-07-02T16:35:53.426Z","phase":"Phase 2","brief_title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","source_id_and_acronym":"NCT02099175 - SINTART 1","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • ifosfamide • etoposide IV • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-03-13"},{"id":"8987832d-b6ef-4a84-b94f-4a7e7e863681","acronym":"","url":"https://clinicaltrials.gov/study/NCT05644249","created_at":"2022-12-09T15:58:26.608Z","updated_at":"2024-07-02T16:35:58.143Z","phase":"","brief_title":"PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer","source_id_and_acronym":"NCT05644249","lead_sponsor":"Vilnius University","biomarkers":" HER-2 • CEACAM5","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • doxorubicin hydrochloride • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2023-01-05"},{"id":"ee9d2948-e174-4b7d-b507-9603eb76e47b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05476432","created_at":"2022-07-27T13:54:36.196Z","updated_at":"2024-07-02T16:35:59.364Z","phase":"Phase 3","brief_title":"HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study","source_id_and_acronym":"NCT05476432","lead_sponsor":"Sun Yat-sen University","biomarkers":" TYMS","pipe":"","alterations":" ","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2022-12-09"},{"id":"2333fc8d-28f2-4288-aae2-5611bad53f1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560949","created_at":"2021-01-18T06:36:46.022Z","updated_at":"2024-07-02T16:36:42.183Z","phase":"Phase 2","brief_title":"Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT01560949","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMAD4","pipe":" | ","alterations":" SMAD4 positive","tags":["SMAD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMAD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 06/14/2012","start_date":" 06/14/2012","primary_txt":" Primary completion: 02/20/2019","primary_completion_date":" 02/20/2019","study_txt":" Completion: 02/20/2019","study_completion_date":" 02/20/2019","last_update_posted":"2020-08-10"},{"id":"dc2690ed-3a36-470d-a962-2be1ae7d7bf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03121807","created_at":"2021-01-18T15:22:51.885Z","updated_at":"2024-07-02T16:36:58.720Z","phase":"","brief_title":"Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer","source_id_and_acronym":"NCT03121807","lead_sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","biomarkers":" IL6 • TNFA • IL10 • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2019-06-21"},{"id":"c133b557-be46-42d3-9c3d-af32e8bdcbee","acronym":"","url":"https://clinicaltrials.gov/study/NCT01472601","created_at":"2021-01-18T06:08:26.884Z","updated_at":"2024-07-02T16:36:59.452Z","phase":"","brief_title":"A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile","source_id_and_acronym":"NCT01472601","lead_sponsor":"Samsung Medical Center","biomarkers":" ERCC1 • GSTP1 • XRCC1","pipe":"","alterations":" ","tags":["ERCC1 • GSTP1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 2660","initiation":"Initiation: 05/24/2011","start_date":" 05/24/2011","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2019-05-20"},{"id":"65218a54-e210-4ab0-8e4e-95815cb207e1","acronym":"FOXAGAST","url":"https://clinicaltrials.gov/study/NCT02486601","created_at":"2021-01-18T11:58:56.400Z","updated_at":"2025-02-25T14:35:41.494Z","phase":"Phase 2","brief_title":"NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma","source_id_and_acronym":"NCT02486601 - FOXAGAST","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" HER-2 • ERCC2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ERCC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 55","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2019-02-27"},{"id":"35d33ff5-4c4a-4713-9f95-ecc89a575890","acronym":"","url":"https://clinicaltrials.gov/study/NCT03329183","created_at":"2021-01-18T16:26:22.714Z","updated_at":"2024-07-02T16:37:02.767Z","phase":"Phase 2","brief_title":"High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28","source_id_and_acronym":"NCT03329183","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1 • UGT1A1 wild-type","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1 • UGT1A1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2019-02-15"},{"id":"7ff72c10-ae33-438e-bf38-eeaa277beb35","acronym":"","url":"https://clinicaltrials.gov/study/NCT01271582","created_at":"2021-01-18T05:08:33.112Z","updated_at":"2024-07-02T16:37:03.411Z","phase":"Phase 4","brief_title":"Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients","source_id_and_acronym":"NCT01271582","lead_sponsor":"Asan Medical Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 1500","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-01-29"},{"id":"2b6fd529-3fad-457b-95e9-e73c6c6ab062","acronym":"","url":"https://clinicaltrials.gov/study/NCT00654160","created_at":"2021-01-18T02:26:06.963Z","updated_at":"2024-07-02T16:37:21.710Z","phase":"Phase 1","brief_title":"Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer","source_id_and_acronym":"NCT00654160","lead_sponsor":"Mayo Clinic","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 12/03/2012","study_completion_date":" 12/03/2012","last_update_posted":"2017-05-25"},{"id":"658fbed6-7655-4cb9-a2ab-b8c6f1c28ae6","acronym":"BOS3","url":"https://clinicaltrials.gov/study/NCT01646554","created_at":"2021-03-24T14:56:57.881Z","updated_at":"2024-07-02T16:37:22.727Z","phase":"Phase 2/3","brief_title":"Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases","source_id_and_acronym":"NCT01646554 - BOS3","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-05-09"},{"id":"ae9c765d-a27e-451d-9978-da5127fe63a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00449137","created_at":"2021-01-18T01:35:21.197Z","updated_at":"2024-07-02T16:37:27.058Z","phase":"Phase 1","brief_title":"Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment","source_id_and_acronym":"NCT00449137","lead_sponsor":"University of Miami","biomarkers":" TYMS","pipe":" | ","alterations":" TYMS expression","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • leucovorin calcium • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2005","start_date":" 06/01/2005","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2016-12-15"}]